Circadia

The company's core technology is a bedside device that uses radar to monitor vital signs like respiratory rate and heart rate, along with patient motion and bed exits, from up to eight feet away without physical contact. This data is analyzed by proprietary AI algorithms to identify trends and predict potential medical events such as congestive heart failure, pneumonia, and sepsis hours or days in advance. The system received its first FDA 510(k) clearance in June 2020 for its C100 model, which focused on contactless respiratory rate monitoring. In November 2024, the C200 system received expanded FDA clearance to include heart rate, motion, and bed exit monitoring.

Circadia operates on a subscription-based business model, providing its technology and services to skilled nursing facilities and other long-term care providers. A team of virtual nurses reviews the collected data and provides 24/7 predictive risk alerts to clinicians, integrating with electronic health records to offer detailed trend analysis. This service helps facilities reduce preventable hospitalizations, lower care costs, and improve patient outcomes. The company's platform is also designed to be reimbursable through Medicare remote patient monitoring codes.